Skip to main content
SpringerLink
Log in

Symptomatic Treatment for Progressive Multiple Sclerosis

  • Chapter
  • First Online:
Progressive Multiple Sclerosis

  • 1897 Accesses

Abstract

Given that MS is a complex, multisystem disease which may cause difficult symptoms in many different systems, the approach to symptom control should be led and coordinated by a physician with a specialist interest in MS. Over the course of the disease, a variable degree of input is likely to be required from primary care physicians as well as specialists in a variety of medical specialities, including, although not limited to, neurology, neurorehabilitation, and palliative care. The role of health professionals in disciplines allied to medicine should not be underestimated and careful attention must be given to patient preference. The needs of caregivers should also be respected and facilitated. In the absence of an available cure for MS, research into improved symptom management should be supported and must include systematic, well-designed clinical trials to evaluate treatments as they emerge.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Thompson AJ. Neurorehabilitation in multiple sclerosis: foundations, facts and fiction. Curr Opin Neurol. 2005;18(3):267–71.

    PubMed  Google Scholar 

  2. The UN standard rules on the equalization of opportunities for persons with disabilities. Geneva: World Health Organisation; 2001. p. 290.

    Google Scholar 

  3. Holper L, et al. Characterization of functioning in multiple sclerosis using the ICF. J Neurol. 2010;257(1):103–13.

    PubMed  Google Scholar 

  4. Kesselring J, et al. Developing the ICF Core Sets for multiple sclerosis to specify functioning. Mult Scler. 2008;14(2):252–4.

    PubMed  CAS  Google Scholar 

  5. National Institute for Clinical Excellence (NICE). Guidance for the management of MS. In: Multiple Sclerosis: national clinical guideline for diagnosis and management in primary and secondary care. London: NICE; 2003.

    Google Scholar 

  6. Multiple Sclerosis International Federation (MSIF). Principles to promote the quality of life of people with multiple sclerosis. London: Multiple Sclerosis International Federation; 2005.

    Google Scholar 

  7. Platform ME, editor. Recommendations on rehabilitation services for persons with multiple sclerosis in Europe. Genoa: Associazione Italiana Sclerosi Multipla; 2004.

    Google Scholar 

  8. Miller D, Rudick RA, Hutchinson M. Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of life. Neurology. 2010;74 Suppl 3:S24–35.

    PubMed  Google Scholar 

  9. Thompson AJ, Toosy AT, Ciccarelli O. Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurol. 2010;9(12):1182–99.

    PubMed  CAS  Google Scholar 

  10. Lance JW. Symposium synopsis. in Spasticity: disordered motor control. Chicago: Year Book; 1980.

    Google Scholar 

  11. Pandyan AD, et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil. 2005;27(1–2):2–6.

    PubMed  CAS  Google Scholar 

  12. Rizzo MA, et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10(5):589–95.

    PubMed  CAS  Google Scholar 

  13. Paisley S, et al. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review. Mult Scler. 2002;8(4):319–29.

    PubMed  CAS  Google Scholar 

  14. Paty DW, Ebers GC. Clinical features. In: Paty DW, Ebers GC, editors. Multiple sclerosis. Philadelphia: F. A. Davis; 1998. p. 135–92.

    Google Scholar 

  15. Francis HP, et al. Does reducing spasticity translate into functional benefit? An exploratory meta-analysis. J Neurol Neurosurg Psychiatry. 2004;75(11):1547–51.

    PubMed  CAS  Google Scholar 

  16. Stevenson VL. Oral medication. In: Stevenson VL, Jarrett L, editors. Spasticity management: a practical multidisciplinary guide. London: Informa Healthcare; 2006. p. 59–70.

    Google Scholar 

  17. Paty DW, Hashimoto SA, Ebers GC. Management of multiple sclerosis and interpretation of clinical trials. In: Paty DW, Ebers GC, editors. Multiple sclerosis. Philadelphia: F. A. Davis; 1998. p. 427–519.

    Google Scholar 

  18. Rosche J, et al. The effects of therapy on spasticity utilizing a motorized exercise-cycle. Spinal Cord. 1997;35(3):176–8.

    PubMed  CAS  Google Scholar 

  19. Kakebeeke TH, Lechner HE, Knapp PA. The effect of passive cycling movements on spasticity after spinal cord injury: preliminary results. Spinal Cord. 2005;43(8):483–8.

    PubMed  CAS  Google Scholar 

  20. Nuyens GE, et al. Reduction of spastic hypertonia during repeated passive knee movements in stroke patients. Arch Phys Med Rehabil. 2002;83(7):930–5.

    PubMed  Google Scholar 

  21. Schmit BD, Dewald JP, Rymer WZ. Stretch reflex adaptation in elbow flexors during repeated passive movements in unilateral brain-injured patients. Arch Phys Med Rehabil. 2000;81(3):269–78.

    PubMed  CAS  Google Scholar 

  22. Katalinic OM, et al. Stretch for the treatment and prevention of contractures. Cochrane Database Syst Rev. 2010;(9):CD007455.

    Google Scholar 

  23. Gao F, et al. Effects of repeated ankle stretching on calf muscle-tendon and ankle biomechanical properties in stroke survivors. Clin Biomech (Bristol, Avon). 2011;26(5):516–22.

    Google Scholar 

  24. Katalinic OM, Harvey LA, Herbert RD. Effectiveness of stretch for the treatment and prevention of contractures in people with neurological conditions: a systematic review. Phys Ther. 2011;91(1):11–24.

    PubMed  Google Scholar 

  25. White LJ, et al. Resistance training improves strength and functional capacity in persons with multiple sclerosis. Mult Scler. 2004;10(6):668–74.

    PubMed  CAS  Google Scholar 

  26. Odeen I, Knutsson E. Evaluation of the effects of muscle stretch and weight load in patients with spastic paraplegia. Scand J Rehabil Med. 1981;13(4):117–21.

    PubMed  CAS  Google Scholar 

  27. Bohannon RW. Tilt table standing for reducing spasticity after spinal cord injury. Arch Phys Med Rehabil. 1993;74(10):1121–2.

    PubMed  CAS  Google Scholar 

  28. Rietberg MB, et al. Exercise therapy for multiple sclerosis. Cochrane Database Syst Rev. 2005;(1):CD003980.

    Google Scholar 

  29. Lockley LJ, Buchanan K. Physical management of spasticity. In: Stevenson VL, Jarrett L, editors. Spasticity management: a practical multidisciplinary guide. London: Informa Healthcare; 2006. p. 37–58.

    Google Scholar 

  30. Stevenson VL. Rehabilitation in practice: spasticity management. Clin Rehabil. 2010;24(4):293–304.

    PubMed  CAS  Google Scholar 

  31. Dalgas U, et al. Muscle fiber size increases following resistance training in multiple sclerosis. Mult Scler. 2010;16(11):1367–76.

    PubMed  CAS  Google Scholar 

  32. Dalgas U, et al. Fatigue, mood and quality of life improve in MS patients after progressive resistance training. Mult Scler. 2010;16(4):480–90.

    PubMed  CAS  Google Scholar 

  33. Golzari Z, et al. Combined exercise training reduces IFN-gamma and IL-17 levels in the plasma and the supernatant of peripheral blood mononuclear cells in women with multiple sclerosis. Int Immunopharmacol. 2010;10(11):1415–9.

    PubMed  CAS  Google Scholar 

  34. Mori F, et al. Transcranial magnetic stimulation primes the effects of exercise therapy in multiple sclerosis. J Neurol. 2011;258(7):1281–7.

    PubMed  Google Scholar 

  35. Centonze D, et al. Repetitive transcranial magnetic stimulation of the motor cortex ameliorates spasticity in multiple sclerosis. Neurology. 2007;68(13):1045–50.

    PubMed  CAS  Google Scholar 

  36. Mori F, et al. Effects of intermittent theta burst stimulation on spasticity in patients with multiple sclerosis. Eur J Neurol. 2010;17(2):295–300.

    PubMed  CAS  Google Scholar 

  37. Nielsen JF, Sinkjaer T, Jakobsen J. Treatment of spasticity with repetitive magnetic stimulation; a double-blind placebo-controlled study. Mult Scler. 1996;2(5):227–32.

    PubMed  CAS  Google Scholar 

  38. Butefisch CM, et al. Mechanisms of use-dependent plasticity in the human motor cortex. Proc Natl Acad Sci USA. 2000;97(7):3661–5.

    PubMed  CAS  Google Scholar 

  39. Holtmaat A, Svoboda K. Experience-dependent structural synaptic plasticity in the mammalian brain. Nat Rev Neurosci. 2009;10(9):647–58.

    PubMed  CAS  Google Scholar 

  40. Cooke SF, Bliss TV. Plasticity in the human central nervous system. Brain. 2006;129(Pt 7):1659–73.

    PubMed  CAS  Google Scholar 

  41. Ratchford JN, et al. A pilot study of functional electrical stimulation cycling in progressive multiple sclerosis. NeuroRehabilitation. 2010;27(2):121–8.

    PubMed  Google Scholar 

  42. Barrett CL, et al. A randomized trial to investigate the effects of functional electrical stimulation and therapeutic exercise on walking performance for people with multiple sclerosis. Mult Scler. 2009;15(4):493–504.

    PubMed  CAS  Google Scholar 

  43. Everaert DG, et al. Does functional electrical stimulation for foot drop strengthen corticospinal connections? Neurorehabil Neural Repair. 2010;24(2):168–77.

    PubMed  Google Scholar 

  44. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev. 2003;(4):CD001332.

    Google Scholar 

  45. Hobart JC, et al. Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol. 2007;6(12):1094–105.

    PubMed  Google Scholar 

  46. Hattab JR. Review of European clinical trials with baclofen. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: disordered motor control. Chicago: Year Book; 1980. p. 71–85.

    Google Scholar 

  47. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group. Neurology. 1994;44(11 Suppl 9):S70–8.

    Google Scholar 

  48. Nance PW, et al. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group. Neurology. 1994;44(11 Suppl 9):S44–51; discussion S51–2.

    PubMed  CAS  Google Scholar 

  49. Smith C, et al. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology. 1994;44(11 Suppl 9):S34–42; discussion S42–3.

    PubMed  CAS  Google Scholar 

  50. Groves L, Shellenberger MK, Davis CS. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv Ther. 1998;15(4):241–51.

    PubMed  CAS  Google Scholar 

  51. Wagstaff AJ, Bryson HM. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997;53(3):435–52.

    PubMed  CAS  Google Scholar 

  52. Krause T, et al. Dantrolene – a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004;59(4):364–73.

    PubMed  CAS  Google Scholar 

  53. Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess. 2003;7(40):iii, ix–x, 1–111.

    PubMed  CAS  Google Scholar 

  54. Mueller ME, et al. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil. 1997;78(5):521–4.

    PubMed  CAS  Google Scholar 

  55. Cutter NC, et al. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehabil. 2000;81(2):164–9.

    PubMed  CAS  Google Scholar 

  56. Formica A, et al. Gabapentin for spasticity: a randomized, double-blind, placebo-controlled trial. Med Clin (Barc). 2005;124(3):81–5.

    Google Scholar 

  57. Fink K, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002;42(2):229–36.

    PubMed  CAS  Google Scholar 

  58. Bradley LJ, Kirker SG. Pregabalin in the treatment of spasticity: a retrospective case series. Disabil Rehabil. 2008;30(16):1230–2.

    PubMed  CAS  Google Scholar 

  59. Rigo JM, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol. 2002;136(5):659–72.

    PubMed  CAS  Google Scholar 

  60. Bedlack RS, et al. Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease. Amyotroph Lateral Scler. 2009;10(4):210–5.

    PubMed  Google Scholar 

  61. Ruegg SJ, Steck AJ, Fuhr P. Levetiracetam improves paroxysmal symptoms in a patient with stiff-person syndrome. Neurology. 2004;62(2):338.

    PubMed  Google Scholar 

  62. Lashch N, Avakian GN. The use of midokalm in patients with multiple sclerosis. Zh Nevrol Psikhiatr Im SS Korsakova. 2000;100(6):24–8.

    Google Scholar 

  63. Stamenova P, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. Eur J Neurol. 2005;12(6):453–61.

    PubMed  CAS  Google Scholar 

  64. Bresolin N, Zucca C, Pecori A. Efficacy and tolerability of eperisone in patients with spastic palsy: a cross-over, placebo-controlled dose-ranging trial. Eur Rev Med Pharmacol Sci. 2009;13(5):365–70.

    PubMed  CAS  Google Scholar 

  65. Bresolin N, Zucca C, Pecori A. Efficacy and tolerability of eperisone and baclofen in spastic palsy: a double-blind randomized trial. Adv Ther. 2009;26(5):563–73.

    PubMed  CAS  Google Scholar 

  66. Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction. 1996;91(11):1585–614.

    PubMed  CAS  Google Scholar 

  67. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646–7.

    CAS  Google Scholar 

  68. Tsou K, et al. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998;83(2):393–411.

    PubMed  CAS  Google Scholar 

  69. Herkenham M, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA. 1990;87(5):1932–6.

    PubMed  CAS  Google Scholar 

  70. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev. 2003;83(3):1017–66.

    PubMed  CAS  Google Scholar 

  71. Van Sickle MD, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005;310(5746):329–32.

    PubMed  Google Scholar 

  72. Skaper SD, et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci USA. 1996;93(9):3984–9.

    PubMed  CAS  Google Scholar 

  73. Alger BE. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol. 2002;68(4):247–86.

    PubMed  CAS  Google Scholar 

  74. Kreitzer AC, Regehr WG. Retrograde signaling by endocannabinoids. Curr Opin Neurobiol. 2002;12(3):324–30.

    PubMed  CAS  Google Scholar 

  75. Berrendero F, et al. Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse. 2001;41(3):195–202.

    PubMed  CAS  Google Scholar 

  76. Baker D, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 2000;404(6773):84–7.

    PubMed  CAS  Google Scholar 

  77. Baker D, et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 2001;15(2):300–2.

    PubMed  CAS  Google Scholar 

  78. Baker D, Pryce G. The endocannabinoid system and multiple sclerosis. Curr Pharm Des. 2008;14(23):2326–36.

    PubMed  CAS  Google Scholar 

  79. Chong MS, et al. Cannabis use in patients with multiple sclerosis. Mult Scler. 2006;12(5):646–51.

    PubMed  CAS  Google Scholar 

  80. Clark AJ, et al. Patterns of cannabis use among patients with multiple sclerosis. Neurology. 2004;62(11):2098–100.

    PubMed  CAS  Google Scholar 

  81. Campbell FA, et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ. 2001;323(7303):13–6.

    PubMed  CAS  Google Scholar 

  82. Zajicek JP, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005;76(12):1664–9.

    PubMed  CAS  Google Scholar 

  83. Malfitano AM, Proto MC, Bifulco M. Cannabinoids in the management of spasticity associated with multiple sclerosis. Neuropsychiatr Dis Treat. 2008;4(5):847–53.

    PubMed  CAS  Google Scholar 

  84. Lakhan SE, Rowland M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurol. 2009;9:59.

    PubMed  Google Scholar 

  85. Smith PF. New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids. Ther Clin Risk Manag. 2010;6:59–63.

    PubMed  CAS  Google Scholar 

  86. Wade DT, et al. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler. 2010;16(6):707–14.

    PubMed  CAS  Google Scholar 

  87. Hobart JC, et al. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain. 2006;129(Pt 1):224–34.

    PubMed  CAS  Google Scholar 

  88. Zajicek JP, Apostu VI. Role of cannabinoids in multiple sclerosis. CNS Drugs. 2011;25(3):187–201.

    PubMed  CAS  Google Scholar 

  89. Honarmand K, et al. Effects of cannabis on cognitive function in patients with multiple sclerosis. Neurology. 2011;76(13):1153–60.

    PubMed  Google Scholar 

  90. Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur J Neurol. 2006;13 Suppl 4:1–9.

    PubMed  Google Scholar 

  91. Ward AB. Spasticity treatment with botulinum toxins. J Neural Transm. 2008;115(4):607–16.

    PubMed  CAS  Google Scholar 

  92. Kabus C, et al. Botulinum toxin in patients with multiple sclerosis. J Neurol. 2006;253 Suppl 1:I26–8.

    PubMed  Google Scholar 

  93. Habek M, et al. The place of the botulinum toxin in the management of multiple sclerosis. Clin Neurol Neurosurg. 2010;112(7):592–6.

    PubMed  Google Scholar 

  94. Giovannelli M, et al. Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil. 2007;21(4):331–7.

    PubMed  CAS  Google Scholar 

  95. Borg J, et al. Rationale and design of a multicentre, double-blind, prospective, randomized, European and Canadian study: evaluating patient outcomes and costs of managing adults with post-stroke focal spasticity. J Rehabil Med. 2011;43(1):15–22.

    PubMed  Google Scholar 

  96. Burbaud P, et al. Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study. J Neurol. 2011;258(9):1670–5.

    PubMed  CAS  Google Scholar 

  97. Elovic EP, et al. Chemodenervation and nerve blocks in the diagnosis and management of spasticity and muscle overactivity. PM R. 2009;1(9):842–51.

    PubMed  Google Scholar 

  98. Yelnik AP, et al. How to clinically assess and treat muscle overactivity in spastic paresis. J Rehabil Med. 2010;42(9):801–7.

    PubMed  Google Scholar 

  99. Bensmail D, et al. Effect of intrathecal baclofen on sleep and respiratory function in patients with spasticity. Neurology. 2006;67(8):1432–6.

    PubMed  CAS  Google Scholar 

  100. Boviatsis EJ, et al. Functional outcome of intrathecal baclofen administration for severe spasticity. Clin Neurol Neurosurg. 2005;107(4):289–95.

    PubMed  Google Scholar 

  101. Zahavi A, et al. Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin. J Neurol Neurosurg Psychiatry. 2004;75(11):1553–7.

    PubMed  CAS  Google Scholar 

  102. Rekand T, Gronning M. Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up. J Rehabil Med. 2011;43(6):511–4.

    PubMed  Google Scholar 

  103. Schuele SU, et al. Incidence of seizures in patients with multiple sclerosis treated with intrathecal baclofen. Neurology. 2005;64(6):1086–7.

    PubMed  CAS  Google Scholar 

  104. Cooper JA, Ridley B. Response of intrathecal baclofen resistance to dose reduction. Neurology. 2006;67(8):1495–6.

    PubMed  Google Scholar 

  105. Kelly RE, Gautier Smith PC. Intrathecal phenol in the treatment of reflex spasms and spasticity. Lancet. 1959;274(7112):1102–5.

    Google Scholar 

  106. Maher RM. Relief of pain in incurable cancer. Lancet. 1955;265(6853):18–20.

    Google Scholar 

  107. Jarrett L, Nandi P, Thompson AJ. Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role? J Neurol Neurosurg Psychiatry. 2002;73(6):705–9.

    PubMed  CAS  Google Scholar 

  108. Boop FA. Evolution of the neurosurgical management of spasticity. J Child Neurol. 2001;16(1):54–7.

    PubMed  CAS  Google Scholar 

  109. Foerster O. On the indications and results of the excision of posterior spinal nerve roots in men. Surg Gynecol Obstet. 1913;16:463–74.

    Google Scholar 

  110. Sherrington C. The integrative action of the central nervous system. London: Archibald Constable; 1906.

    Google Scholar 

  111. Gros C, et al. La radicotomie selective posterieure dans le traitement neurochirurgical de l’hypertonie pyramidale. Neurochirurgie. 1967;13:505–18.

    PubMed  CAS  Google Scholar 

  112. Salame K, et al. Surgical treatment of spasticity by selective posterior rhizotomy: 30 years experience. Isr Med Assoc J. 2003;5(8):543–6.

    PubMed  Google Scholar 

  113. Maarrawi J, et al. Long-term functional results of selective peripheral neurotomy for the treatment of spastic upper limb: prospective study in 31 patients. J Neurosurg. 2006;104(2):215–25.

    PubMed  Google Scholar 

  114. Sindou M, Mertens P. Selective neurotomy of the tibial nerve for treatment of the spastic foot. Neurosurgery. 1988;23(6):738–44.

    PubMed  CAS  Google Scholar 

  115. O’Connor AB, et al. Pain associated with multiple sclerosis: systematic review and proposed classification. Pain. 2008;137(1):96–111.

    PubMed  Google Scholar 

  116. Hirsh AT, et al. Prevalence and impact of pain in multiple sclerosis: physical and psychologic contributors. Arch Phys Med Rehabil. 2009;90(4):646–51.

    PubMed  Google Scholar 

  117. Brichetto G, et al. Symptomatic medication use in multiple sclerosis. Mult Scler. 2003;9(5):458–60.

    PubMed  CAS  Google Scholar 

  118. Moulin DE, Foley KM, Ebers GC. Pain syndromes in multiple sclerosis. Neurology. 1988;38(12):1830–4.

    PubMed  CAS  Google Scholar 

  119. Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis – prevalence and clinical characteristics. Eur J Pain. 2005;9(5):531–42.

    PubMed  CAS  Google Scholar 

  120. Vermote R, Ketelaer P, Carton H. Pain in multiple sclerosis patients. A prospective study using the Mc Gill Pain Questionnaire. Clin Neurol Neurosurg. 1986;88(2):87–93.

    PubMed  CAS  Google Scholar 

  121. Boneschi FM, et al. Lifetime and actual prevalence of pain and headache in multiple sclerosis. Mult Scler. 2008;14(4):514–21.

    Google Scholar 

  122. Solaro C, et al. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology. 2004;63(5):919–21.

    PubMed  CAS  Google Scholar 

  123. Hadjimichael O, et al. Persistent pain and uncomfortable sensations in persons with multiple sclerosis. Pain. 2007;127(1–2):35–41.

    PubMed  Google Scholar 

  124. Ehde DM, et al. Chronic pain in a large community sample of persons with multiple sclerosis. Mult Scler. 2003;9(6):605–11.

    PubMed  Google Scholar 

  125. Brochet B, et al. Pain and quality of life in the early stages after multiple sclerosis diagnosis: a 2-year longitudinal study. Clin J Pain. 2009;25(3):211–7.

    PubMed  Google Scholar 

  126. Svendsen KB, et al. Pain in patients with multiple sclerosis: a population-based study. Arch Neurol. 2003;60(8):1089–94.

    PubMed  Google Scholar 

  127. Putzki N, Katsarava Z. Headache in multiple sclerosis. Curr Pain Headache Rep. 2010;14(4):316–20.

    PubMed  Google Scholar 

  128. Kister I, et al. Tension-type headache and migraine in multiple sclerosis. Curr Pain Headache Rep. 2010;14(6):441–8.

    PubMed  Google Scholar 

  129. Welch KM, et al. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache. 2001;41(7):629–37.

    PubMed  CAS  Google Scholar 

  130. Knight YE, Goadsby PJ. The periaqueductal grey matter modulates trigeminovascular input: a role in migraine? Neuroscience. 2001;106(4):793–800.

    PubMed  CAS  Google Scholar 

  131. Pollmann W, Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs. 2008;22(4):291–324.

    PubMed  Google Scholar 

  132. Treede RD, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630–5.

    PubMed  CAS  Google Scholar 

  133. Grasso MG, et al. Pain in multiple sclerosis: a clinical and instrumental approach. Mult Scler. 2008;14(4):506–13.

    PubMed  CAS  Google Scholar 

  134. Attal N, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13(11):1153–69.

    PubMed  CAS  Google Scholar 

  135. Tan T, et al. Pharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance. BMJ. 2010;340:c1079.

    PubMed  Google Scholar 

  136. Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics. 2009;6(4):713–37.

    PubMed  CAS  Google Scholar 

  137. Iskedjian M, et al. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin. 2007;23(1):17–24.

    PubMed  CAS  Google Scholar 

  138. Karst M, Wippermann S, Ahrens J. Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs. 2010;70(18):2409–38.

    PubMed  CAS  Google Scholar 

  139. Rowbotham MC, et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003;348(13):1223–32.

    PubMed  CAS  Google Scholar 

  140. Breuer B, et al. A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. Clin Ther. 2007;29(9):2022–30.

    PubMed  CAS  Google Scholar 

  141. Kalman S, et al. Morphine responsiveness in a group of well-defined multiple sclerosis patients: a study with i.v. morphine. Eur J Pain. 2002;6(1):69–80.

    PubMed  CAS  Google Scholar 

  142. Chitsaz A, et al. Sensory complaints of the upper extremities in multiple sclerosis: relative efficacy of nortriptyline and transcutaneous electrical nerve stimulation. Clin J Pain. 2009;25(4):281–5.

    PubMed  Google Scholar 

  143. Kumar K, Hunter G, Demeria D. Spinal cord stimulation in treatment of chronic benign pain: challenges in treatment planning and present status, a 22-year experience. Neurosurgery. 2006;58(3):481–96; discussion 481–96.

    PubMed  Google Scholar 

  144. Osenbach RK. Motor cortex stimulation for intractable pain. Neurosurg Focus. 2006;21(6):E7.

    PubMed  Google Scholar 

  145. Levy R, Deer TR, Henderson J. Intracranial neurostimulation for pain control: a review. Pain Physician. 2010;13(2):157–65.

    PubMed  Google Scholar 

  146. Patwardhan RV, et al. Neurosurgical treatment of multiple sclerosis. Neurol Res. 2006;28(3):320–5.

    PubMed  Google Scholar 

  147. Sadiq SA, Poopatana CA. Intrathecal baclofen and morphine in multiple sclerosis patients with severe pain and spasticity. J Neurol. 2007;254(10):1464–5.

    PubMed  CAS  Google Scholar 

  148. Dahm PO, et al. Long-term intrathecal (i.t.) infusion of bupivacaine relieved intractable pain and spasticity in a patient with multiple sclerosis. Eur J Pain. 1998;2(1):81–5.

    PubMed  Google Scholar 

  149. Solaro C, Tanganelli P. Tiagabine for treating painful tonic spasms in multiple sclerosis: a pilot study. J Neurol Neurosurg Psychiatry. 2004;75(2):341.

    PubMed  CAS  Google Scholar 

  150. Hawker K, Frohman E, Racke M. Levetiracetam for phasic spasticity in multiple sclerosis. Arch Neurol. 2003;60(12):1772–4.

    PubMed  Google Scholar 

  151. Solaro C, et al. Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. Mult Scler. 2000;6(3):192–3.

    PubMed  CAS  Google Scholar 

  152. Morgan JC, Hess DC, Sethi KD. Botulinum toxin treatment of painful tonic spasms in multiple sclerosis. Neurology. 2004;62(11):2143; author reply 2143.

    PubMed  Google Scholar 

  153. Restivo DA, et al. Botulinum toxin treatment of painful tonic spasms in multiple sclerosis. Neurology. 2003;61(5):719–20.

    PubMed  CAS  Google Scholar 

  154. Sakurai M, Kanazawa I. Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine. J Neurol Sci. 1999;162(2):162–8.

    PubMed  CAS  Google Scholar 

  155. Putzki N, et al. Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis. Eur J Neurol. 2009;16(2):262–7.

    PubMed  CAS  Google Scholar 

  156. Rushton JG, Olafson RA. Trigeminal neuralgia associated with multiple sclerosis: report of 35 cases. Arch Neurol. 1965;13(4):383–6.

    PubMed  CAS  Google Scholar 

  157. Love S, Gradidge T, Coakham HB. Trigeminal neuralgia due to multiple sclerosis: ultrastructural findings in trigeminal rhizotomy specimens. Neuropathol Appl Neurobiol. 2001;27(3):238–44.

    PubMed  CAS  Google Scholar 

  158. Love S, Coakham HB. Trigeminal neuralgia: pathology and pathogenesis. Brain. 2001;124(Pt 12):2347–60.

    PubMed  CAS  Google Scholar 

  159. Cruccu G, et al. Trigeminal neuralgia and pain related to multiple sclerosis. Pain. 2009;143(3):186–91.

    PubMed  CAS  Google Scholar 

  160. Espir ML, Millac P. Treatment of paroxysmal disorders in multiple sclerosis with carbamazepine (Tegretol). J Neurol Neurosurg Psychiatry. 1970;33(4):528–31.

    PubMed  CAS  Google Scholar 

  161. Solaro C, et al. Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. Neurol Sci. 2005;25(6):307–10.

    PubMed  CAS  Google Scholar 

  162. Ramsaransing G, Zwanikken C, De Keyser J. Worsening of symptoms of multiple sclerosis associated with carbamazepine. BMJ. 2000;320(7242):1113.

    PubMed  CAS  Google Scholar 

  163. Lunardi G, et al. Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia. Neurology. 1997;48(6):1714–7.

    PubMed  CAS  Google Scholar 

  164. Leandri M, et al. Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis. J Neurol. 2000;247(7):556–8.

    PubMed  CAS  Google Scholar 

  165. Solaro C, et al. Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis. Eur Neurol. 2000;44(1):45–8.

    PubMed  CAS  Google Scholar 

  166. Khan OA. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology. 1998;51(2):611–4.

    PubMed  CAS  Google Scholar 

  167. Solaro C, et al. An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology. 1998;51(2):609–11.

    PubMed  CAS  Google Scholar 

  168. Zvartau-Hind M, et al. Topiramate relieves refractory trigeminal neuralgia in MS patients. Neurology. 2000;55(10):1587–8.

    PubMed  CAS  Google Scholar 

  169. Solaro C, et al. Topiramate relieves idiopathic and symptomatic trigeminal neuralgia. J Pain Symptom Manage. 2001;21(5):367–8.

    PubMed  CAS  Google Scholar 

  170. DMKG study group. Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis. J Neurol. 2003;250(5):542–5.

    Google Scholar 

  171. Reder AT, Arnason BG. Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue. Neurology. 1995;45(6):1097–100.

    PubMed  CAS  Google Scholar 

  172. Zakrzewska JM, et al. Patient reports of satisfaction after microvascular decompression and partial sensory rhizotomy for trigeminal neuralgia. Neurosurgery. 2005;56(6):1304–11; discussion 1311–2.

    PubMed  Google Scholar 

  173. Brisman R. Trigeminal neuralgia and multiple sclerosis. Arch Neurol. 1987;44(4):379–81.

    PubMed  CAS  Google Scholar 

  174. Eldridge PR, et al. Microvascular decompression for trigeminal neuralgia in patients with multiple sclerosis. Stereotact Funct Neurosurg. 2003;81(1–4):57–64.

    PubMed  CAS  Google Scholar 

  175. Athanasiou TC, et al. Some patients with multiple sclerosis have neurovascular compression causing their trigeminal neuralgia and can be treated effectively with MVD: report of five cases. Br J Neurosurg. 2005;19(6):463–8.

    PubMed  CAS  Google Scholar 

  176. Broggi G, et al. Operative findings and outcomes of microvascular decompression for trigeminal neuralgia in 35 patients affected by multiple sclerosis. Neurosurgery. 2004;55(4):830–8; discussion 838–9.

    PubMed  Google Scholar 

  177. Broggi G, et al. Role of microvascular decompression in trigeminal neuralgia and multiple sclerosis. Lancet. 1999;354(9193):1878–9.

    PubMed  CAS  Google Scholar 

  178. Broggi G, et al. Microvascular decompression for trigeminal neuralgia: comments on a series of 250 cases, including 10 patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000;68(1):59–64.

    PubMed  CAS  Google Scholar 

  179. Sandell T, Eide PK. The effect of microvascular decompression in patients with multiple sclerosis and trigeminal neuralgia. Neurosurgery. 2010;67(3):749–53; discussion 753–4.

    PubMed  Google Scholar 

  180. Zakrzewska JM, McMillan R. Trigeminal neuralgia: the diagnosis and management of this excruciating and poorly understood facial pain. Postgrad Med J. 2011;87(1028):410–6.

    PubMed  Google Scholar 

  181. Harries AM, Mitchell RD. Percutaneous glycerol rhizotomy for trigeminal neuralgia: safety and efficacy of repeat procedures. Br J Neurosurg. 2011;25(2):268–72.

    PubMed  Google Scholar 

  182. Pickett GE, Bisnaire D, Ferguson GG. Percutaneous retrogasserian glycerol rhizotomy in the treatment of tic douloureux associated with multiple sclerosis. Neurosurgery. 2005;56(3):537–45; discussion 537–45.

    PubMed  Google Scholar 

  183. Kanpolat Y, et al. Percutaneous controlled radiofrequency rhizotomy in the management of patients with trigeminal neuralgia due to multiple sclerosis. Acta Neurochir (Wien). 2000;142(6):685–9; discussion 689–90.

    CAS  Google Scholar 

  184. Zorro O, et al. Gamma knife radiosurgery for multiple sclerosis-related trigeminal neuralgia. Neurology. 2009;73(14):1149–54.

    PubMed  CAS  Google Scholar 

  185. Verheul JB, et al. Gamma Knife surgery for trigeminal neuralgia: a review of 450 consecutive cases. J Neurosurg. 2010;113(Suppl):160–7.

    PubMed  Google Scholar 

  186. Nurmikko TJ. Pathophysiology of MS-related trigeminal neuralgia. Pain. 2009;143(3):165–6.

    PubMed  Google Scholar 

  187. Minagar A, Sheremata WA. Glossopharyngeal neuralgia and MS. Neurology. 2000;54(6):1368–70.

    PubMed  CAS  Google Scholar 

  188. Al-Araji AH, Oger J. Reappraisal of Lhermitte’s sign in multiple sclerosis. Mult Scler. 2005;11(4):398–402.

    PubMed  Google Scholar 

  189. Rudick R, Goodkin D. Multiple sclerosis therapeutics. London: Martin Dunitz Ltd.; 1999.

    Google Scholar 

  190. Hemmett L, et al. What drives quality of life in multiple sclerosis? QJM. 2004;97(10):671–6.

    PubMed  CAS  Google Scholar 

  191. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci. 2008;9(6):453–66.

    PubMed  CAS  Google Scholar 

  192. Betts CD, D’Mellow MT, Fowler CJ. Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1993;56(3):245–50.

    PubMed  CAS  Google Scholar 

  193. Fowler CJ, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009;80(5):470–7.

    PubMed  CAS  Google Scholar 

  194. de Seze M, et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler. 2007;13(7):915–28.

    PubMed  Google Scholar 

  195. Khan F, et al. A randomised controlled trial: outcomes of bladder rehabilitation in persons with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010;81(9):1033–8.

    PubMed  CAS  Google Scholar 

  196. O’Riordan JI, et al. Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis? J Urol. 1995;153(4):1114–6.

    PubMed  Google Scholar 

  197. Prasad RS, Smith SJ, Wright H. Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study. Clin Rehabil. 2003;17(1):42–7.

    PubMed  CAS  Google Scholar 

  198. McConnell JD, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–98.

    PubMed  CAS  Google Scholar 

  199. National Institute for Health and Clinical Excellence. Infection control. Prevention of healthcare-associated infection in primary and community care. London: National Institute for Health and Clinical Excellence; 2003.

    Google Scholar 

  200. Lekka E, Lee LK. Successful treatment with intradetrusor Botulinum-A toxin for urethral urinary leakage (catheter bypassing) in patients with end-staged multiple sclerosis and indwelling suprapubic catheters. Eur Urol. 2006;50(4):806–9; discussion 809–10.

    PubMed  Google Scholar 

  201. Ethans KD, et al. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med. 2004;27(3):214–8.

    PubMed  Google Scholar 

  202. Gajewski JB, Awad SA. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol. 1986;135(5):966–8.

    PubMed  CAS  Google Scholar 

  203. Amend B, et al. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol. 2008;53(5):1021–8.

    PubMed  CAS  Google Scholar 

  204. Weese DL, et al. Intravesical oxybutynin chloride: experience with 42 patients. Urology. 1993;41(6):527–30.

    PubMed  CAS  Google Scholar 

  205. Fader M, et al. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial. J Urol. 2007;177(1):208–13; discussion 213.

    PubMed  CAS  Google Scholar 

  206. Herschorn S, et al. Efficacy of botulinum toxin a injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185(6):2229–35.

    PubMed  CAS  Google Scholar 

  207. Khan S, et al. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol. 2011;185(4):1344–9.

    PubMed  CAS  Google Scholar 

  208. Bosma R, et al. Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol Scand. 2005;112(1):1–5.

    PubMed  CAS  Google Scholar 

  209. British National Formulary 61. London: BMJ Group and Pharma Press; 2011.

    Google Scholar 

  210. Reynard JM, et al. A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. Br J Urol. 1998;81(2):215–8.

    PubMed  CAS  Google Scholar 

  211. Freeman RM, et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct. 2006;17(6):636–41.

    PubMed  CAS  Google Scholar 

  212. Brady CM, et al. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler. 2004;10(4):425–33.

    PubMed  CAS  Google Scholar 

  213. Kavia RB, et al. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler. 2010;16(11):1349–59.

    PubMed  CAS  Google Scholar 

  214. Ruggieri Sr MR. Cannabinoids: potential targets for bladder dysfunction. Handb Exp Pharmacol. 2011;202:425–51.

    PubMed  CAS  Google Scholar 

  215. Wiart L, et al. The effects of capsaicin on the neurogenic hyperreflexic detrusor. A double blind placebo controlled study in patients with spinal cord disease. Preliminary results. Spinal Cord. 1998;36(2):95–9.

    PubMed  CAS  Google Scholar 

  216. Kim JH, et al. Intravesical resiniferatoxin for refractory detrusor hyperreflexia: a multicenter, blinded, randomized, placebo-controlled trial. J Spinal Cord Med. 2003;26(4):358–63.

    PubMed  Google Scholar 

  217. Marinkovic SP, Gillen LM. Sacral neuromodulation for multiple sclerosis patients with urinary retention and clean intermittent catheterization. Int Urogynecol J Pelvic Floor Dysfunct. 2010;21(2):223–8.

    Google Scholar 

  218. Tjon Eng Soe SH, et al. Multiple sclerosis patients with bladder dysfunction have decreased symptoms after electro-acupuncture. Mult Scler. 2009;15(11):1376–7.

    PubMed  CAS  Google Scholar 

  219. Kabay S, et al. The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. Neurourol Urodyn. 2009;28(8):964–8.

    PubMed  Google Scholar 

  220. Fjorback MV, et al. Event driven electrical stimulation of the dorsal penile/clitoral nerve for management of neurogenic detrusor overactivity in multiple sclerosis. Neurourol Urodyn. 2006;25(4):349–55.

    PubMed  Google Scholar 

  221. Delong J, Tighiouart H, Stoffel J. Urinary diversion/reconstruction for cases of catheter intolerant secondary progressive multiple sclerosis with refractory urinary symptoms. J Urol. 2011;185(6):2201–6.

    PubMed  Google Scholar 

  222. Betts CD, et al. Erectile dysfunction in multiple sclerosis. Associated neurological and neurophysiological deficits, and treatment of the condition. Brain. 1994;117(Pt 6):1303–10.

    PubMed  Google Scholar 

  223. Zorzon M, et al. Sexual dysfunction in multiple sclerosis: a case–control study. I. Frequency and comparison of groups. Mult Scler. 1999;5(6):418–27.

    PubMed  CAS  Google Scholar 

  224. Lilius HG, Valtonen EJ, Wikstrom J. Sexual problems in patients suffering from multiple sclerosis. J Chronic Dis. 1976;29(10):643–7.

    PubMed  CAS  Google Scholar 

  225. O’Sullivan SS, Hardiman O. Detection rates of sexual dysfunction amongst patients with multiple sclerosis in an outpatient setting – can this be improved? Ir Med J. 2006;99(10):304–6.

    PubMed  Google Scholar 

  226. Zivadinov R, et al. Sexual dysfunction in multiple sclerosis: II. Correlation analysis. Mult Scler. 1999;5(6):428–31.

    PubMed  CAS  Google Scholar 

  227. Rees PM, Fowler CJ, Maas CP. Sexual function in men and women with neurological disorders. Lancet. 2007;369(9560):512–25.

    PubMed  Google Scholar 

  228. Fletcher SG, et al. Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and management. Nat Clin Pract Urol. 2009;6(2):96–107.

    PubMed  Google Scholar 

  229. Safarinejad MR. Evaluation of the safety and efficacy of sildenafil citrate for erectile dysfunction in men with multiple sclerosis: a double-blind, placebo controlled, randomized study. J Urol. 2009;181(1):252–8.

    PubMed  CAS  Google Scholar 

  230. Fowler CJ, et al. A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005;76(5):700–5.

    PubMed  CAS  Google Scholar 

  231. Pifarre P, et al. Sildenafil (Viagra) ameliorates clinical symptoms and neuropathology in a mouse model of multiple sclerosis. Acta Neuropathol. 2011;121(4):499–508.

    PubMed  CAS  Google Scholar 

  232. Lombardi G, Macchiarella A, Del Popolo G. Efficacy and safety of tadalafil for erectile dysfunction in patients with multiple sclerosis. J Sex Med. 2010;7(6):2192–200.

    PubMed  Google Scholar 

  233. DasGupta R, Fowler CJ. Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. Drugs. 2003;63(2):153–66.

    PubMed  CAS  Google Scholar 

  234. Safarinejad MR. Midodrine for the treatment of organic anejaculation but not spinal cord injury: a prospective randomized placebo-controlled double-blind clinical study. Int J Impot Res. 2009;21(4):213–20.

    PubMed  CAS  Google Scholar 

  235. Dasgupta R, et al. Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. J Urol. 2004;171(3):1189–93; discussion 1193.

    PubMed  CAS  Google Scholar 

  236. Chia YW, et al. Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction. J Neurol. 1995;242(2):105–8.

    PubMed  CAS  Google Scholar 

  237. Hinds JP, Eidelman BH, Wald A. Prevalence of bowel dysfunction in multiple sclerosis. A population survey. Gastroenterology. 1990;98(6):1538–42.

    PubMed  CAS  Google Scholar 

  238. Sullivan SN, Ebers GC. Gastrointestinal dysfunction in multiple sclerosis. Gastroenterology. 1983;84(6):1640.

    PubMed  CAS  Google Scholar 

  239. Hennessey A, et al. Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. J Neurol. 1999;246(11):1027–32.

    PubMed  CAS  Google Scholar 

  240. Nortvedt MW, et al. Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis. Mult Scler. 2007;13(1):106–12.

    PubMed  CAS  Google Scholar 

  241. Wiesel PH, et al. Pathophysiology and management of bowel dysfunction in multiple sclerosis. Eur J Gastroenterol Hepatol. 2001;13(4):441–8.

    PubMed  CAS  Google Scholar 

  242. Emmanuel A. Managing neurogenic bowel dysfunction. Clin Rehabil. 2010;24(6):483–8.

    PubMed  Google Scholar 

  243. Muller-Lissner SA. Effect of wheat bran on weight of stool and gastrointestinal transit time: a meta analysis. Br Med J (Clin Res Ed). 1988;296(6622):615–7.

    CAS  Google Scholar 

  244. Wiesel PH, et al. Gut focused behavioural treatment (biofeedback) for constipation and faecal incontinence in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000;69(2):240–3.

    PubMed  CAS  Google Scholar 

  245. McClurg D, et al. Abdominal massage for the alleviation of constipation symptoms in people with multiple sclerosis: a randomized controlled feasibility study. Mult Scler. 2011;17(2):223–33.

    PubMed  Google Scholar 

  246. House JG, Stiens SA. Pharmacologically initiated defecation for persons with spinal cord injury: effectiveness of three agents. Arch Phys Med Rehabil. 1997;78(10):1062–5.

    PubMed  CAS  Google Scholar 

  247. Gill KP, et al. Defecography in multiple sclerosis patients with severe constipation. Radiology. 1994;191(2):553–6.

    PubMed  CAS  Google Scholar 

  248. Emmanuel A. Review of the efficacy and safety of transanal irrigation for neurogenic bowel dysfunction. Spinal Cord. 2010;48(9):664–73.

    PubMed  CAS  Google Scholar 

  249. Preziosi G, Emmanuel A. Neurogenic bowel dysfunction: pathophysiology, clinical manifestations and treatment. Expert Rev Gastroenterol Hepatol. 2009;3(4):417–23.

    PubMed  Google Scholar 

  250. Randell N, et al. Does a colostomy alter quality of life in patients with spinal cord injury? A controlled study. Spinal Cord. 2001;39(5):279–82.

    PubMed  CAS  Google Scholar 

  251. Swingler RJ, Compston DA. The morbidity of multiple sclerosis. Q J Med. 1992;83(300):325–37.

    PubMed  CAS  Google Scholar 

  252. Alusi SH, et al. A study of tremor in multiple sclerosis. Brain. 2001;124(Pt 4):720–30.

    PubMed  CAS  Google Scholar 

  253. Pittock SJ, et al. Prevalence of tremor in multiple sclerosis and associated disability in the Olmsted County population. Mov Disord. 2004;19(12):1482–5.

    PubMed  Google Scholar 

  254. Koch M, et al. Tremor in multiple sclerosis. J Neurol. 2007;254(2):133–45.

    PubMed  Google Scholar 

  255. Sandyk R, Dann LC. Weak electromagnetic fields attenuate tremor in multiple sclerosis. Int J Neurosci. 1994;79(3–4):199–212.

    PubMed  CAS  Google Scholar 

  256. Dahlin-Webb SR. A weighted wrist cuff. Am J Occup Ther. 1986;40(5):363–4.

    PubMed  CAS  Google Scholar 

  257. Aisen ML, et al. The effect of mechanical damping loads on disabling action tremor. Neurology. 1993;43(7):1346–50.

    PubMed  CAS  Google Scholar 

  258. Armutlu K, Karabudak R, Nurlu G. Physiotherapy approaches in the treatment of ataxic multiple sclerosis: a pilot study. Neurorehabil Neural Repair. 2001;15(3):203–11.

    PubMed  CAS  Google Scholar 

  259. Feys P, et al. Assistive technology to improve PC interaction for people with intention tremor. J Rehabil Res Dev. 2001;38(2):235–43.

    PubMed  CAS  Google Scholar 

  260. Vergaro E, et al. Adaptive robot training for the treatment of incoordination in Multiple Sclerosis. J Neuroeng Rehabil. 2010;7:37.

    PubMed  Google Scholar 

  261. Mills RJ, Yap L, Young CA. Treatment for ataxia in multiple sclerosis. Cochrane Database Syst Rev. 2007;(1):CD005029.

    Google Scholar 

  262. Henkin Y, Herishanu YO. Primidone as a treatment for cerebellar tremor in multiple sclerosis – two case reports. Isr J Med Sci. 1989;25(12):720–1.

    PubMed  CAS  Google Scholar 

  263. Aisen ML, et al. Glutethimide treatment of disabling action tremor in patients with multiple sclerosis and traumatic brain injury. Arch Neurol. 1991;48(5):513–5.

    PubMed  CAS  Google Scholar 

  264. Weiss N, et al. Attenuation of cerebellar tremor with implantation of an intrathecal baclofen pump: the role of gamma-aminobutyric acidergic pathways. Case report. J Neurosurg. 2003;99(4):768–71.

    PubMed  Google Scholar 

  265. Schroeder A, et al. Successful treatment of cerebellar ataxia and tremor in multiple sclerosis with topiramate: a case report. Clin Neuropharmacol. 2010;33(6):317–8.

    PubMed  Google Scholar 

  266. Sabra AF, et al. Treatment of action tremor in multiple sclerosis with isoniazid. Neurology. 1982;32(8):912–3.

    PubMed  CAS  Google Scholar 

  267. Duquette P, Pleines J, du Souich P. Isoniazid for tremor in multiple sclerosis: a controlled trial. Neurology. 1985;35(12):1772–5.

    PubMed  CAS  Google Scholar 

  268. Morrow J, et al. Isoniazid and action tremor in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1985;48(3):282–3.

    PubMed  CAS  Google Scholar 

  269. Francis DA, Grundy D, Heron JR. The response to isoniazid of action tremor in multiple sclerosis and its assessment using polarised light goniometry. J Neurol Neurosurg Psychiatry. 1986;49(1):87–9.

    PubMed  CAS  Google Scholar 

  270. Koller WC. Pharmacologic trials in the treatment of cerebellar tremor. Arch Neurol. 1984;41(3):280–1.

    PubMed  CAS  Google Scholar 

  271. Feys P, et al. The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis. Mult Scler. 2009;15(3):371–8.

    PubMed  CAS  Google Scholar 

  272. Monaca-Charley C, et al. Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis. J Neurol. 2003;250(10):1190–4.

    PubMed  CAS  Google Scholar 

  273. Hallett M, et al. Controlled trial of isoniazid therapy for severe postural cerebellar tremor in multiple sclerosis. Neurology. 1985;35(9):1374–7.

    PubMed  CAS  Google Scholar 

  274. Bozek CB, et al. A controlled trial of isoniazid therapy for action tremor in multiple sclerosis. J Neurol. 1987;234(1):36–9.

    PubMed  CAS  Google Scholar 

  275. Sechi GP, et al. Treatment of cerebellar tremors with carbamazepine: a controlled trial with long-term follow-up. Neurology. 1989;39(8):1113–5.

    PubMed  CAS  Google Scholar 

  276. Rice GP, et al. Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor. J Neurol Neurosurg Psychiatry. 1997;62(3):282–4.

    PubMed  CAS  Google Scholar 

  277. Zajicek J, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362(9395):1517–26.

    PubMed  CAS  Google Scholar 

  278. Fox P, et al. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology. 2004;62(7):1105–9.

    PubMed  CAS  Google Scholar 

  279. Wade DT, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10(4):434–41.

    PubMed  CAS  Google Scholar 

  280. Yap L, Kouyialis A, Varma TR. Stereotactic neurosurgery for disabling tremor in multiple sclerosis: thalamotomy or deep brain stimulation? Br J Neurosurg. 2007;21(4):349–54.

    PubMed  CAS  Google Scholar 

  281. Johnson RD, et al. Perioperative seizures following deep brain stimulation in patients with multiple sclerosis. Br J Neurosurg. 2010;24(3):289–90.

    PubMed  Google Scholar 

  282. Jahanshahi M, et al. Effects on cognition of stereotactic lesional surgery for the treatment of tremor in multiple sclerosis. Behav Neurol. 2008;20(1–2):1–9.

    PubMed  Google Scholar 

  283. Timmermann L, et al. Deep brain stimulation for tremor in multiple sclerosis: consensus recommendations of the German Deep Brain Stimulation Association. Nervenarzt. 2009;80(6):673–7.

    PubMed  CAS  Google Scholar 

  284. Figved N, et al. Caregiver burden in multiple sclerosis: the impact of neuropsychiatric symptoms. J Neurol Neurosurg Psychiatry. 2007;78(10):1097–102.

    PubMed  Google Scholar 

  285. Patten SB, et al. Major depression in multiple sclerosis: a population-based perspective. Neurology. 2003;61(11):1524–7.

    PubMed  CAS  Google Scholar 

  286. Chwastiak L, et al. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry. 2002;159(11):1862–8.

    PubMed  Google Scholar 

  287. Harel Y, Barak Y, Achiron A. Dysregulation of affect in multiple sclerosis: new phenomenological approach. Psychiatry Clin Neurosci. 2007;61(1):94–8.

    PubMed  Google Scholar 

  288. Feinstein A. Mood disorders in multiple sclerosis and the effects on cognition. J Neurol Sci. 2006;245(1–2):63–6.

    PubMed  Google Scholar 

  289. Demaree HA, Gaudino E, DeLuca J. The relationship between depressive symptoms and cognitive dysfunction in multiple sclerosis. Cogn Neuropsychiatry. 2003;8(3):161–71.

    PubMed  Google Scholar 

  290. Figved N, et al. Relationship of cognitive impairment to psychiatric symptoms in multiple sclerosis. Mult Scler. 2008;14(8):1084–90.

    PubMed  CAS  Google Scholar 

  291. McGuigan C, Hutchinson M. Unrecognised symptoms of depression in a community-based population with multiple sclerosis. J Neurol. 2006;253(2):219–23.

    PubMed  CAS  Google Scholar 

  292. Lincoln NB, et al. Evaluation of an adjustment group for people with multiple sclerosis and low mood: a randomized controlled trial. Mult Scler. 2011;17(10):1250–7.

    Google Scholar 

  293. Rigby SA, Thornton EW, Young CA. A randomized group intervention trial to enhance mood and self-efficacy in people with multiple sclerosis. Br J Health Psychol. 2008;13(Pt 4):619–31.

    PubMed  CAS  Google Scholar 

  294. Dennison L, Moss-Morris R. Cognitive-behavioral therapy: what benefits can it offer people with multiple sclerosis? Expert Rev Neurother. 2010;10(9):1383–90.

    PubMed  Google Scholar 

  295. Thomas PW, et al. Psychological interventions for multiple sclerosis. Cochrane Database Syst Rev. 2006;(1):CD004431.

    Google Scholar 

  296. Koch MW, et al. Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database Syst Rev. 2011;(2):CD007295.

    Google Scholar 

  297. Price A, et al. Antidepressants for the treatment of depression in neurological disorders: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry. 2011;82(8):914–23.

    PubMed  Google Scholar 

  298. Patten SB, Svenson LW, Metz LM. Psychotic disorders in MS: population-based evidence of an association. Neurology. 2005;65(7):1123–5.

    PubMed  Google Scholar 

  299. Surridge D. An investigation into some psychiatric aspects of multiple sclerosis. Br J Psychiatry. 1969;115(524):749–64.

    PubMed  CAS  Google Scholar 

  300. Kosmidis MH, et al. Psychotic features associated with multiple sclerosis. Int Rev Psychiatry. 2010;22(1):55–66.

    PubMed  Google Scholar 

  301. Sechi GP, et al. Dexamethasone-induced schizoaffective-like state in multiple sclerosis: prophylaxis and treatment with carbamazepine. Clin Neuropharmacol. 1987;10(5):453–7.

    PubMed  CAS  Google Scholar 

  302. Minden SL, Orav J, Schildkraut JJ. Hypomanic reactions to ACTH and prednisone treatment for multiple sclerosis. Neurology. 1988;38(10):1631–4.

    PubMed  CAS  Google Scholar 

  303. Goeb JL, et al. Acute delirium, delusion, and depression during IFN-beta-1a therapy for multiple sclerosis: a case report. Clin Neuropharmacol. 2003;26(1):5–7.

    PubMed  CAS  Google Scholar 

  304. Manfredi G, et al. Persistent interferon-ss-1b-induced psychosis in a patient with multiple sclerosis. Psychiatry Clin Neurosci. 2010;64(5):584–6.

    PubMed  Google Scholar 

  305. Feinstein A, du Boulay G, Ron MA. Psychotic illness in multiple sclerosis. A clinical and magnetic resonance imaging study. Br J Psychiatry. 1992;161:680–5.

    PubMed  CAS  Google Scholar 

  306. Chong SA, Ko SM. Clozapine treatment of psychosis associated with multiple sclerosis. Can J Psychiatry. 1997;42(1):90–1.

    PubMed  CAS  Google Scholar 

  307. Safferman AZ, et al. The use of clozapine in neurologic disorders. J Clin Psychiatry. 1994;55(Suppl B):98–101.

    PubMed  Google Scholar 

  308. Hussain A, Belderbos S. Risperidone depot in the treatment of psychosis associated with multiple sclerosis – a case report. J Psychopharmacol. 2008;22(8):925–6.

    PubMed  CAS  Google Scholar 

  309. Davids E, Hartwig U, Gastpar M. Antipsychotic treatment of psychosis associated with multiple sclerosis. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(4):743–4.

    PubMed  CAS  Google Scholar 

  310. Schiffer RB, Wineman NM, Weitkamp LR. Association between bipolar affective disorder and multiple sclerosis. Am J Psychiatry. 1986;143(1):94–5.

    PubMed  CAS  Google Scholar 

  311. Paparrigopoulos T, et al. The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect and behaviour. Int Rev Psychiatry. 2010;22(1):14–21.

    PubMed  Google Scholar 

  312. Feinstein A, et al. Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. Arch Neurol. 1997;54(9):1116–21.

    PubMed  CAS  Google Scholar 

  313. Pioro EP, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68(5):693–702.

    PubMed  CAS  Google Scholar 

  314. Panitch HS, et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol. 2006;59(5):780–7.

    PubMed  CAS  Google Scholar 

  315. Schiffer RB, Herndon RM, Rudick RA. Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med. 1985;312(23):1480–2.

    PubMed  CAS  Google Scholar 

  316. Iannaccone S, Ferini-Strambi L. Pharmacologic treatment of emotional lability. Clin Neuropharmacol. 1996;19(6):532–5.

    PubMed  CAS  Google Scholar 

  317. Nahas Z, et al. Rapid response of emotional incontinence to selective serotonin reuptake inhibitors. J Neuropsychiatry Clin Neurosci. 1998;10(4):453–5.

    PubMed  CAS  Google Scholar 

  318. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008;7(12):1139–51.

    PubMed  Google Scholar 

  319. Portaccio E, et al. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis. Neurology. 2009;73(7):498–503.

    PubMed  CAS  Google Scholar 

  320. Potagas C, et al. Cognitive impairment in different MS subtypes and clinically isolated syndromes. J Neurol Sci. 2008;267(1–2):100–6.

    PubMed  Google Scholar 

  321. Amato MP, et al. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol. 2001;58(10):1602–6.

    PubMed  CAS  Google Scholar 

  322. Denney DR, Sworowski LA, Lynch SG. Cognitive impairment in three subtypes of multiple sclerosis. Arch Clin Neuropsychol. 2005;20(8):967–81.

    PubMed  Google Scholar 

  323. Rao SM, et al. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology. 1991;41(5):692–6.

    PubMed  CAS  Google Scholar 

  324. Jennekens-Schinkel A, et al. Cognition in patients with multiple sclerosis after four years. J Neurol Sci. 1990;99(2–3):229–47.

    PubMed  CAS  Google Scholar 

  325. Kujala P, Portin R, Ruutiainen J. The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up. Brain. 1997;120(Pt 2):289–97.

    PubMed  Google Scholar 

  326. Fischer JS, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol. 2000;48(6):885–92.

    PubMed  CAS  Google Scholar 

  327. Patti F, et al. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. Mult Scler. 2010;16(1):68–77.

    PubMed  CAS  Google Scholar 

  328. Pliskin NH, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology. 1996;47(6):1463–8.

    PubMed  CAS  Google Scholar 

  329. Flechter S, et al. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study. Isr Med Assoc J. 2007;9(6):457–9.

    PubMed  CAS  Google Scholar 

  330. Kappos L, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370(9585):389–97.

    PubMed  CAS  Google Scholar 

  331. Mattioli F, Stampatori C, Capra R. The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study. Neurol Sci. 2011;32(1):83–8.

    PubMed  Google Scholar 

  332. D’Intino G, et al. Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats. Proc Natl Acad Sci USA. 2005;102(8):3070–5.

    PubMed  Google Scholar 

  333. Krupp LB, et al. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology. 2011;76(17):1500–7.

    PubMed  CAS  Google Scholar 

  334. Shaygannejad V, et al. Effects of rivastigmine on memory and cognition in multiple sclerosis. Can J Neurol Sci. 2008;35(4):476–81.

    PubMed  Google Scholar 

  335. Villoslada P, et al. Memantine induces reversible neurologic impairment in patients with MS. Neurology. 2009;72(19):1630–3.

    PubMed  CAS  Google Scholar 

  336. Lovera JF, et al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. 2010;16(6):715–23.

    PubMed  CAS  Google Scholar 

  337. Geisler MW, et al. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch Neurol. 1996;53(2):185–8.

    PubMed  CAS  Google Scholar 

  338. Lovera J, et al. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial. Mult Scler. 2007;13(3):376–85.

    PubMed  CAS  Google Scholar 

  339. Morrow SA, et al. The effects of L-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial. J Neurol. 2009;256(7):1095–102.

    PubMed  CAS  Google Scholar 

  340. Oleen-Burkey M, Hadjimichael O, Vollmer T. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes. 2008;6:100.

    PubMed  Google Scholar 

  341. Krupp L. Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease. Mult Scler. 2006;12(4):367–8.

    PubMed  Google Scholar 

  342. Lerdal A, et al. A prospective study of patterns of fatigue in multiple sclerosis. Eur J Neurol. 2007;14(12):1338–43.

    PubMed  CAS  Google Scholar 

  343. Smith MM, Arnett PA. Factors related to employment status changes in individuals with multiple sclerosis. Mult Scler. 2005;11(5):602–9.

    PubMed  Google Scholar 

  344. Judica E, et al. Impact of fatigue on the efficacy of rehabilitation in multiple sclerosis. J Neurol. 2011;258(5):835–9.

    PubMed  Google Scholar 

  345. Veauthier C, et al. Fatigue in multiple sclerosis is closely related to sleep disorders: a polysomnographic cross-sectional study. Mult Scler. 2011;17(5):613–22.

    PubMed  CAS  Google Scholar 

  346. Kaminska M, et al. Sleep disorders and fatigue in multiple sclerosis: evidence for association and interaction. J Neurol Sci. 2011;302(1–2):7–13.

    PubMed  CAS  Google Scholar 

  347. Braley TJ, Chervin RD. Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep. 2010;33(8):1061–7.

    PubMed  Google Scholar 

  348. Schwid SR, et al. A randomized controlled study of the acute and chronic effects of cooling therapy for MS. Neurology. 2003;60(12):1955–60.

    PubMed  Google Scholar 

  349. van Kessel K, et al. A randomized controlled trial of cognitive behavior therapy for multiple sclerosis fatigue. Psychosom Med. 2008;70(2):205–13.

    PubMed  Google Scholar 

  350. Thomas PW, et al. Multi-centre parallel arm randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based cognitive behavioural approach to managing fatigue in people with multiple sclerosis. BMC Neurol. 2010;10:43.

    PubMed  Google Scholar 

  351. Piatkowski J, Kern S, Ziemssen T. Effect of BEMER magnetic field therapy on the level of fatigue in patients with multiple sclerosis: a randomized, double-blind controlled trial. J Altern Complement Med. 2009;15(5):507–11.

    PubMed  Google Scholar 

  352. Carvalho ML, et al. A randomized placebo-controlled cross-over study using a low frequency magnetic field in the treatment of fatigue in multiple sclerosis. Mult Scler. 2012;18(1):82–9.

    PubMed  Google Scholar 

  353. Metz LM, et al. The effect of immunomodulatory treatment on multiple sclerosis fatigue. J Neurol Neurosurg Psychiatry. 2004;75(7):1045–7.

    PubMed  CAS  Google Scholar 

  354. Putzki N, et al. Multiple sclerosis associated fatigue during natalizumab treatment. J Neurol Sci. 2009;285(1–2):109–13.

    PubMed  CAS  Google Scholar 

  355. Yildiz M, Tettenborn B, Putzki N. Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate. Eur Neurol. 2011;65(4):231–2.

    PubMed  Google Scholar 

  356. Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and multiple sclerosis. Evidence-based management strategies for fatigue in multiple sclerosis. Washington: Paralyzed Veterans of America; 1998.

    Google Scholar 

  357. Branas P, et al. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technol Assess. 2000;4(27):1–61.

    PubMed  CAS  Google Scholar 

  358. Pucci E, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2007;(1):CD002818.

    Google Scholar 

  359. Taus C, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2003;(2):CD002818.

    Google Scholar 

  360. Lange R, et al. Modafinil effects in multiple sclerosis patients with fatigue. J Neurol. 2009;256(4):645–50.

    PubMed  CAS  Google Scholar 

  361. Moller F, et al. HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis. Mult Scler. 2011;17(8):1002–9.

    PubMed  CAS  Google Scholar 

  362. Weinshenker BG, et al. A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology. 1992;42(8):1468–71.

    PubMed  CAS  Google Scholar 

  363. Krupp LB, et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology. 1995;45(11):1956–61.

    PubMed  CAS  Google Scholar 

  364. Goodman AD, et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler. 2007;13(3):357–68.

    PubMed  CAS  Google Scholar 

  365. Solari JJ, Pozzi AG, Ceballos NR. Seasonal changes in the activity of cytochrome P450(C17) from the testis of Bufo arenarum. J Comp Physiol B. 2002;172(8):685–90.

    PubMed  CAS  Google Scholar 

  366. Sheean GL, et al. An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain. 1998;121(Pt 5):967–75.

    PubMed  Google Scholar 

  367. Rossini PM, et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler. 2001;7(6):354–8.

    PubMed  CAS  Google Scholar 

  368. Flet L, et al. 3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study. J Neurol. 2010;257(6):937–46.

    PubMed  CAS  Google Scholar 

  369. Tejani AM, et al. Carnitine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2010;(2):CD007280.

    Google Scholar 

  370. Tomassini V, et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci. 2004;218(1–2):103–8.

    PubMed  CAS  Google Scholar 

  371. Kim E, et al. American ginseng does not improve fatigue in multiple sclerosis: a single center randomized double-blind placebo-controlled crossover pilot study. Mult Scler. 2011;17(12):1523–6.

    PubMed  CAS  Google Scholar 

  372. Caminero A, Bartolome M. Sleep disturbances in multiple sclerosis. J Neurol Sci. 2011;309(1–2):86–91.

    PubMed  Google Scholar 

  373. Brass SD, et al. Sleep disorders in patients with multiple sclerosis. Sleep Med Rev. 2010;14(2):121–9.

    PubMed  Google Scholar 

  374. Newman NJ. Multiple sclerosis and related demyelinating diseases. In: Miller NR, Newman NJ, editors. Walsh and Hoyt’s clinical neuro-ophthalmology. Baltimore: Williams and Wilkins; 1998. p. 5539–76.

    Google Scholar 

  375. Ganley JP. Uveitis and multiple sclerosis: an overview. In: Saari KM, editor. Uveitis update. Amsterdam: Excerpta Medica; 1984. p. 345–9.

    Google Scholar 

  376. Rushton D, Cox N. A new optical treatment for oscillopsia. J Neurol Neurosurg Psychiatry. 1987;50(4):411–5.

    PubMed  CAS  Google Scholar 

  377. Starck M, et al. Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. J Neurol. 2010;257(3):322–7.

    PubMed  Google Scholar 

  378. Leigh RJ, et al. Crossover trial of gabapentin and memantine as treatment for acquired nystagmus. Ann Neurol. 2010;67(5):676–80.

    PubMed  Google Scholar 

  379. Strupp M, et al. Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology. 2003;61(2):165–70.

    PubMed  CAS  Google Scholar 

  380. Kalla R, et al. 4-aminopyridine improves downbeat nystagmus, smooth pursuit, and VOR gain. Neurology. 2004;62(7):1228–9.

    PubMed  CAS  Google Scholar 

  381. Kalla R, et al. Comparison of 10-mg Doses of 4-Aminopyridine and 3,4-Diaminopyridine for the Treatment of Downbeat Nystagmus. J Neuroophthalmol. 2011;31(4):320–5.

    PubMed  Google Scholar 

  382. Averbuch-Heller L. Acquired nystagmus. Curr Treat Options Neurol. 1999;1(1):68–73.

    PubMed  Google Scholar 

  383. Menon GJ, Thaller VT. Therapeutic external ophthalmoplegia with bilateral retrobulbar botulinum toxin- an effective treatment for acquired nystagmus with oscillopsia. Eye (Lond). 2002;16(6):804–6.

    CAS  Google Scholar 

  384. Ruben ST, et al. The use of botulinum toxin for treatment of acquired nystagmus and oscillopsia. Ophthalmology. 1994;101(4):783–7.

    PubMed  CAS  Google Scholar 

  385. Adams WE, Leavitt JA, Holmes JM. Strabismus surgery for internuclear ophthalmoplegia with exotropia in multiple sclerosis. J AAPOS. 2009;13(1):13–5.

    PubMed  Google Scholar 

  386. Thomas FJ, Wiles CM. Dysphagia and nutritional status in multiple sclerosis. J Neurol. 1999;246(8):677–82.

    PubMed  CAS  Google Scholar 

  387. Giusti A, Giambuzzi M. Management of dysphagia in patients affected by multiple sclerosis: state of the art. Neurol Sci. 2008;29 Suppl 4:S364–6.

    PubMed  Google Scholar 

  388. Alfonsi E, et al. An electrophysiological approach to the diagnosis of neurogenic dysphagia: implications for botulinum toxin treatment. J Neurol Neurosurg Psychiatry. 2010;81(1):54–60.

    PubMed  CAS  Google Scholar 

  389. Restivo DA, et al. Botulinum toxin improves dysphagia associated with multiple sclerosis. Eur J Neurol. 2011;18(3):486–90.

    PubMed  CAS  Google Scholar 

  390. Marrosu F, et al. Vagal nerve stimulation improves cerebellar tremor and dysphagia in multiple sclerosis. Mult Scler. 2007;13(9):1200–2.

    PubMed  CAS  Google Scholar 

  391. Beukelman DR, Kraft GH, Freal J. Expressive communication disorders in persons with multiple sclerosis: a survey. Arch Phys Med Rehabil. 1985;66(10):675–7.

    PubMed  CAS  Google Scholar 

  392. Hartelius L, Svensson P. Speech and swallowing symptoms associated with Parkinson’s disease and multiple sclerosis: a survey. Folia Phoniatr Logop. 1994;46(1):9–17.

    PubMed  CAS  Google Scholar 

  393. Hartelius L, Runmarker B, Andersen O. Prevalence and characteristics of dysarthria in a multiple-sclerosis incidence cohort: relation to neurological data. Folia Phoniatr Logop. 2000;52(4):160–77.

    PubMed  CAS  Google Scholar 

  394. Darley FL, Brown JR, Goldstein NP. Dysarthria in multiple sclerosis. J Speech Hear Res. 1972;15(2):229–45.

    PubMed  CAS  Google Scholar 

  395. Parker M, et al. Automatic speech recognition and training for severely dysarthric users of assistive technology: the STARDUST project. Clin Linguist Phon. 2006;20(2–3):149–56.

    PubMed  Google Scholar 

  396. Blanco Y, et al. Midbrain lesions and paroxysmal dysarthria in multiple sclerosis. Mult Scler. 2008;14(5):694–7.

    PubMed  CAS  Google Scholar 

  397. Valentino P, et al. Lamotrigine therapy for paroxysmal dysarthria caused by multiple sclerosis: a case report. J Neurol. 2011;258(7):1349–50.

    PubMed  CAS  Google Scholar 

  398. Voiculescu V, Pruskauer-Apostol B, Alecu C. Treatment with acetazolamide of brain-stem and spinal paroxysmal disturbances in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1975;38(2):191–3.

    PubMed  CAS  Google Scholar 

  399. Lensch E, Jost WH. Autonomic disorders in multiple sclerosis. Autoimmune Dis. 2011;2011:803841.

    PubMed  CAS  Google Scholar 

  400. Davis SL, et al. Thermoregulation in multiple sclerosis. J Appl Physiol. 2010;109(5):1531–7.

    PubMed  Google Scholar 

  401. Higginson IJ, et al. Symptom prevalence and severity in people severely affected by multiple sclerosis. J Palliat Care. 2006;22(3):158–65.

    PubMed  Google Scholar 

  402. O’Brien T. Neurodegenerative disease. In: Addington-Hall JM, Higginson IJ, editors. Palliative care for non-cancer patients. Oxford: Oxford University Press; 2001. p. 44–55.

    Google Scholar 

  403. Kumpfel T, et al. Palliative care in patients with severe multiple sclerosis: two case reports and a survey among German MS neurologists. Palliat Med. 2007;21(2):109–14.

    PubMed  CAS  Google Scholar 

  404. Higginson IJ, et al. Is short-term palliative care cost-effective in multiple sclerosis? A randomized phase II trial. J Pain Symptom Manage. 2009;38(6):816–26.

    PubMed  Google Scholar 

  405. Edmonds P, et al. Palliative care for people severely affected by multiple sclerosis: evaluation of a novel palliative care service. Mult Scler. 2010;16(5):627–36.

    PubMed  Google Scholar 

  406. Golla H, et al. Unmet needs of severely affected multiple sclerosis patients: the health professionals’ view. Palliat Med. 2012;26(2):139–51.

    PubMed  Google Scholar 

  407. Department of Health Long-term Conditions NSF Team. The National Service Framework for Long-term Conditions. London: DH; 2005. Department of Health, UK Government.

    Google Scholar 

  408. Guideline Development Group. Longterm neurological conditions: management at the interface between neurology, rehabilitation and palliative care. London: Royal College of Physicians; 2008.

    Google Scholar 

  409. Campbell CW, Jones EJ, Merrills J. Palliative and end-of-life care in advanced Parkinson’s disease and multiple sclerosis. Clin Med. 2010;10(3):290–2.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Institute of Clinical Neuroscience, University of Bristol, Frenchay Hospital, Bristol, BS16 1JB, UK

    Claire M. Rice M.A., M.R.C.P., Ph.D.

  2. Department of Neurology, Frenchay Hospital, Frenchay Park Road, Bristol, BS16 1LE, UK

    Alastair Wilkins M.A., M.B., B.Chir, Ph.D., FRCP

Authors
  1. Claire M. Rice M.A., M.R.C.P., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alastair Wilkins M.A., M.B., B.Chir, Ph.D., FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claire M. Rice M.A., M.R.C.P., Ph.D. .

Editor information

Editors and Affiliations

  1. , Department of Neurology, Frenchay Hospital, Frenchay Park Road, Bristol, BS16 1LE, United Kingdom

    Alastair Wilkins

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Rice, C.M., Wilkins, A. (2013). Symptomatic Treatment for Progressive Multiple Sclerosis. In: Wilkins, A. (eds) Progressive Multiple Sclerosis. Springer, London. https://doi.org/10.1007/978-1-4471-2395-8_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2395-8_8

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2394-1

  • Online ISBN: 978-1-4471-2395-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation